Abstracts - faqs.org

Abstracts

Zoology and wildlife conservation

Search abstracts:
Abstracts » Zoology and wildlife conservation

Genetically engineered foods get green light

Article Abstract:

The Food and Drug Administration (FDA) has proposed regulatory guidelines for genetically engineered food products that would control the products but not the methods used to make them. The FDA's action is tantamount to official approval of the idea that such foods are not so different from ordinary foods that special government rules are necessary to safeguard public health. The guidelines will probably become standard policy despite the objections of consumer protection advocates who say it will allow the genetic engineering industry to regulate itself.

Author: Gershon, Diane
Publisher: Macmillan Publishing Ltd.
Publication Name: Nature
Subject: Zoology and wildlife conservation
ISSN: 0028-0836
Year: 1992
Product information, Genetic engineering

User Contributions:

Comment about this article or add new information about this topic:

CAPTCHA


Bovine growth hormone meets new safety concerns

Article Abstract:

A General Accounting Office report on recombinant bovine growth hormone (rbGH) called on the Food and Drug Administration (FDA) to delay approving rbGH until further research clarifies possible indirect effects on humans. The hormone is administered to dairy cows to increase milk output. The report chides the FDA for not investigating whether the udder inflammation (mastitis) occurring more frequently among cows receiving rbGH might prompt a greater use of antibiotics and so increase antibiotic residues in milk and beef products.

Author: Gershon, Diane
Publisher: Macmillan Publishing Ltd.
Publication Name: Nature
Subject: Zoology and wildlife conservation
ISSN: 0028-0836
Year: 1992
Health aspects, Reports, United States. Government Accountability Office, Bovine somatotropin

User Contributions:

Comment about this article or add new information about this topic:

CAPTCHA


Frustrated by regulatory delays at FDA, biotech companies warm to user fees

Article Abstract:

Three biotechnology trade associations have endorsed user fees as a means for the Food and Drug Administration (FDA) to speed approval of new drugs. The Industrial Biotechnology Assn, the Assn of Biotechnology Cos and the Pharmaceutical Manufacturers Assn were initially reluctant to subsidize the FDA but now concur that the fees will help to get new products approved more quickly by allowing the FDA to employ 600 additional scientists. Budget constraints are preventing the FDA from hiring the extra personnel on its own.

Author: Gershon, Diane
Publisher: Macmillan Publishing Ltd.
Publication Name: Nature
Subject: Zoology and wildlife conservation
ISSN: 0028-0836
Year: 1992
User fees, Drug approval

User Contributions:

Comment about this article or add new information about this topic:

CAPTCHA


Subjects list: Laws, regulations and rules, Biotechnology industry, Biotechnology industries, United States. Food and Drug Administration
Similar abstracts:
  • Abstracts: The importance of valuing resources: host weight and contender age as determinants of parasitoid wasp contest outcomes
  • Abstracts: The stability of forest biodiversity. Neutral theory and relative species abundance in ecology. Optimal shapes of compact strings
  • Abstracts: Functional cloning of TUG as a regulator of GLUT4 glucose transporter trafficking. CAP defines a second signalling pathway required for insulin-stimulated glucose treatment
  • Abstracts: Evidence from U-Th dating against Northern Hemisphere forcing of the penultimate deglaciation. Extending the Vostok ice-core record of palaeoclimate to the penultimate glacial period
  • Abstracts: From cell line to brain. Genetic evidence that relative synaptic efficacy biases the outcome of synaptic competition
This website is not affiliated with document authors or copyright owners. This page is provided for informational purposes only. Unintentional errors are possible.
Some parts © 2025 Advameg, Inc.